CA
CBIO

Cliff Asness’s Crescent Biopharma CBIO Stock Holding History

Cliff Asness’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-976
Closed -$226K – 2269
2021
Q2 		$226K Sell
976
-1,145
-54% -$291K ﹤0.01% 2117
2021
Q1 		$638K Buy
+2,121
New +$760K ﹤0.01% 1744
2020
Q4 		– Sell
-490
Closed -$150K – 2212
2020
Q3 		$150K Buy
490
+7
+1% +$2.68K ﹤0.01% 2101
2020
Q2 		$182K Sell
483
-62
-11% -$17.6K ﹤0.01% 2008
2020
Q1 		$124K Buy
545
+356
+188% +$136K ﹤0.01% 1941
2019
Q4 		$100K Buy
+189
New +$102K ﹤0.01% 2082

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cliff Asness's CBIO Position: Q3 2021 in Review

Cliff Asness sold out of Crescent Biopharma (CBIO) in Q3 2021, closing a stake of 976 shares — an estimated $226K sold.

Cliff Asness first reported a position in CBIO in Q4 2019 and held it in 6 quarters. The position peaked at $638K in Q1 2021. 47 funds tracked by Wall St. Rank hold CBIO as of Q3 2021.

  • Cliff Asness reported no remaining Crescent Biopharma position as of Q3 2021 after selling out during the quarter.
  • Cliff Asness sold 976 Crescent Biopharma shares in Q3 2021, an estimated $226K.
  • Cliff Asness first reported a position in Crescent Biopharma in Q4 2019 and held it in 6 quarters.
  • Cliff Asness's Crescent Biopharma position peaked at $638K in Q1 2021.
  • 47 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2021.

Based on AQR Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.